Enhancing CRISPR deletion via pharmacological delay of DNA-PKcs.

Bosch-Guiteras, Núria; Uroda, Tina; Guillen-Ramirez, Hugo A.; Riedo, Rahel; Gazdhar, Amiq; Esposito, Roberta; Pulido-Quetglas, Carlos; Zimmer, Yitzhak; Medová, Michaela; Johnson, Rory (2021). Enhancing CRISPR deletion via pharmacological delay of DNA-PKcs. Genome research, 31(3), pp. 461-471. Cold Spring Harbor, N.Y 10.1101/gr.265736.120

Preview

Text Gazdhar_Enhancing.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (1MB) | Preview

CRISPR-Cas9 deletion (CRISPR-del) is the leading approach for eliminating DNA from mammalian cells and underpins a variety of genome-editing applications. Target DNA, defined by a pair of double-strand breaks (DSBs), is removed during nonhomologous end-joining (NHEJ). However, the low efficiency of CRISPR-del results in laborious experiments and false-negative results. By using an endogenous reporter system, we show that repression of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-an early step in NHEJ-yields substantial increases in DNA deletion. This is observed across diverse cell lines, gene delivery methods, commercial inhibitors, and guide RNAs, including those that otherwise display negligible activity. We further show that DNA-PKcs inhibition can be used to boost the sensitivity of pooled functional screens and detect true-positive hits that would otherwise be overlooked. Thus, delaying the kinetics of NHEJ relative to DSB formation is a simple and effective means of enhancing CRISPR-deletion.

Interest & Impact

Downloads

104 since deposited on 17 Feb 2021
24 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item